Global Nuclear Medicine Isotopes Market Report, Latest Trends, Industry Opportunity & Forecast to 2027

Nuclear Medicine Industry 2021Absolute Markets insights has published report titled Nuclear Medicine Industry 2021.basically Nuclear Medicine Industry is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine.

Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics.

They are simple substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders.

The medicine imaging helps to gather distinctive info that always cannot be obtained mistreatment different imaging techniques and offers the scope to spot sickness in its earliest stages.Access Full Report Details and Order this Premium Report @ https://www.absolutemarketsinsights.com/reports/Nuclear-Medicine-Market-2018-2026-32Major Key Players:Cardinal Health, Inc., Medtronic, Minimally Invasive Therapies, Ion Beam Applications S.A (IBA Worldwide), Lantheus Medical Imaging Inc., General Electric Company, Bracco Imaging S.p.A, Bayer AG, Advanced Medical Isotope Corporation, Alliance Medical Limited, Alseres Pharmaceuticals, Inc., Avid Radiopharmaceuticals, Inc., Actinium Pharmaceuticals, Inc., Immunomedics, Inc., Jubilant Pharma LLC, Mallinckrodt Pharmaceuticals, Medi-Radiopharma Co., Ltd., Peregrine Pharmaceuticals, Inc.,Positron Corporation and Nordion (Canada) Inc. amongst others.Nuclear Medicine Industry- By ProductDiagnostic MedicineSPECT RadiopharmaceuticalsPET RadiopharmaceuticalsTherapeutic MedicineBeta EmittersAlpha EmittersBrachytherapy IsotopesMarket SegmentationNuclear Medicine Industry- By ApplicationDiagnostic ApplicationOncologyCardiologyNeurologyOthersTherapeutic ApplicationThyroidBone MetastasisLymphomaEndocrine TumorsOthersMarket By RegionNorth AmericaU.S.Rest of North AmericaEuropeFranceThe UKSpainGermanyItalyRest of EuropeAsia PacificChinaJapanIndiaSoutheast AsiaAustraliaRest of Asia PacificMiddle East and AfricaGCC CountriesSouthern AfricaRest of Middle East and AfricaLatin AmericaBrazilRest of Latin AmericaContact us:Shreyas TannaPhone: +91-740-024-2424Absolute Markets InsightsEmail: [email protected]

The global nuclear medicine market size is expected to reach USD 12.6 billion by 2027, expanding at a CAGR of 9.5%, according to a new report by Radiant Insights, Inc. Research and development of advanced technologies by the key players for diagnosis and treatment of diseases is expected to drive the radiopharmaceuticals market.

For instance, in May 2019, GE Healthcare with Indi Molecular, Inc., collaborated to develop Protein Catalyzed Capture (PCC) technology and immune cell-targeted PET tracer candidates.

Moreover, high prevalence of cancer in emerging Asian countries is creating huge demand for radiopharmaceuticals in diagnosing the disease.

For instance, in October 2018, with the support of ASML, The Institute For Radioelements (IRE) developed and built an electron beamline to manufacture medical isotope molybdenum 99 (Mo-99).

In addition, research centers and hospitals are launching novel nuclear medicine techniques to treat various diseases at an affordable cost as compared to the existing treatments.

Further key findings from the study suggest: • In 2019, the SPECT segment had dominated the market owing to integration of SPECT with X-ray/CT that has gained more acceptance and proved to be useful in many clinical situations due to its high accuracy • PET diagnostic nuclear medicine is expected to witness the fastest growth over the forecast period owing to the increasing adoption of high resolution PET scanners • In case of the therapeutic segment, brachytherapy is anticipated to be the fastest growing segment due to the higher radiation protection as compared to other treatment options • The oncology application segment dominated the nuclear medicine market in 2019 owing to the presence of pipeline drugs and high prevalence of cancer • The market in Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and development of radiopharmaceuticals for diagnosis and treatment of various diseases • Key players in the market include companies such as Eckert and Ziegler Group Nordion, Inc.; Bracco Imaging S.p.A.; and GE Healthcare as well as government organizations such as Department of Atomic Energy and Australian Nuclear Science and Technology Organization (ANSTO).

Nuclear Medicine is a breakthrough branch of medicine, used for the diagnosis and treatment of a variety of life-threatening disorders. Nuclear Medicine Technology helps physicians study and treat disorders right to their cellular activity, showcasing the behavior of various organs inside the body. With relevant, vital information, disorders can be diagnosed and treated as early as possible, causing success rates to increase.

How does Nuclear Medicine Technology work?

The first step of Nuclear Medicine involves a radiopharmaceutical, which is simply a small amount of radioactive substance combined with a natural chemical such as glucose. This is most often injected into the patients, with a short wait till the next time, to allow the radiopharmaceutical to spread throughout the body, to all the organs. An imaging procedure then uses a camera to record the presence of any abnormal activity, which occurs when the glucose begins interacting with abnormal cells. These areas are then highlighted on images produced, allowing to determine the presence, location, and amount of abnormal cells in the body.

What are the uses of Nuclear Medicine Technology for diagnosis?

A PET CT scan is the most common form of Nuclear Medicine, which provides in-depth information on the functioning of the body. This can be used to diagnose a variety of ailments:

• Types of cancer such as Thyroid Cancer, and Lung Cancer, among others.
• Brain disorders such as Alzheimer’s, Parkinson’s disease, Dementia, etc.
• Heart Ailments such as identifying the effects of Heart Attack, Coronary Artery Disease, and more.

Nuclear Medicine can also be used to check if a certain disorder has reoccurred after successful treatment.

How is Nuclear Medicine Technology used for treatment?

Nuclear Medicine Technology is used to determine the effectiveness of present treatment plans, to test if certain treatments are effective. Radioactive iodine is considered an effective treatment for Hyperthyroidism, or overactive thyroid. Various approaches to treating certain disorders harness the effects of Nuclear Medicine Technology.

Is Nuclear Medicine safe?

Nuclear Medicine uses only small amounts of radiation, especially in diagnostic procedures, which are safe for the body to handle. This is far less than the amount of radiation we are exposed to in the outside world. However, it is not suitable for everyone, especially fetuses, babies, and young children. Hence pregnant women are advised not to undergo any diagnostic procedures involving radiation. Patients are typically given a list of precautions, to ensure a safe procedure.

If considering Nuclear Medicine Technology, make sure to visit experts, who can skillfully conduct procedures and ensure a positive outcome. PET CT Scan Mumbai is among the best PET scan centres in India, owing to the precise and accurate scanning technology available in our state-of-the-art clinic. Aiding in a timely diagnosis of cancer and other ailments since its establishment, we use cutting-edge Discovery IQ technology that produces high-quality scans in a quick time, with maximum patient comfort. With highly-skilled technicians and radiologists, we ensure an accurate diagnosis of the highest standard of excellence, which has helped numerous patients overcome their condition with ease. Get an estimate, today

Nuclear Medicine Market Research Report by Product Type (Diagnostic nuclear medicine and Therapeutic radiopharmaceuticals), Application (Diagnostic applications and Therapeutic applications), End-user (Hospitals & diagnostic centers, Research institutes, and Others), and Region–Global Forecast T0 2023The “Nuclear Medicine Market” In-Depth competition analysis of the major companies in the report, sector of the report includes the market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue.Nuclear Medicine Market Research Report by Product Type (Diagnostic nuclear medicine and Therapeutic radiopharmaceuticals), Application (Diagnostic applications and Therapeutic applications), End-user (Hospitals diagnostic centers, Research institutes, and Others), and Region–Global Forecast to 2023 Market Segment by Regions, regional analysis covers 2019-2023:North America(United States, Canada and Mexico)Europe(Germany, France, UK, Russia and Italy)Asia-Pacific(China, Japan, Korea, India and Southeast Asia)South America(Brazil, Argentina, Colombia etc.

)Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria and South Africa).Nuclear Medicine Market Research Coverage:Changing market dynamics of the industryTo get a comprehensive overview of the Nuclear Medicine Market.Historical, current and projected market size in terms of volume and valueIn-depth market segmentationCompetitive landscapeThe Nuclear Medicine Market sample report will provide valuable insight with an emphasis on the global market including some of the major players such As, Cardinal Health, GE Healthcare, Bayer, Bracco Imaging, Curium, Lantheus Medical Imaging, Nordion Inc., Advanced Accelerators Applications, Mallinckrodt Pharmaceuticals, Jubliant Lifesciences, and Medtronic plc.The report also appraises the supervisory scenarios which affect various decisions in the market.

With all the data congregated and scrutinized using SWOT analysis, there is a vibrant picture of the competitive scenario of the Global Nuclear Medicine Market.

Openings for the future market growth were uncovered and preoccupied competitive threats also textured.Reasons to Purchase this ReportQualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factorsProvision of market value (USD Billion) data for each segment and sub-segmentIndicates the region and segment that is expected to witness the fastest growth as well as to dominate the marketAnalysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each regionThe competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiledThe research analysts provide an elaborate description of the value chain and its distributor analysis.

This Nuclear Medicine Market study provides comprehensive data which enhances the understanding, scope and application of this report.

Access Complete Detailed TOC Research Report at https://www.marketresearchfuture.com/reports/nuclear-medicine-market-6674 About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Nuclear Medicine Market Research Report by Product Type (Diagnostic nuclear medicine and Therapeutic radiopharmaceuticals), Application (Diagnostic applications and Therapeutic applications), End-user (Hospitals & diagnostic centers, Research institutes, and Others), and Region - Forecast to 2027Market OverviewThe global nuclear medicine market is expected to develop at a CAGR of 6.2 percent from 2018 to 2023, according to Market Research Future (MRFR)’s study.

By the end of 2023, the market's value is projected to increase by USD 5.43 billion.

Market DynamicsNuclear medicine has accurate diagnostic capabilities and is useful in the early detection of cancer and other diseases including cardiovascular disorders.

A major driver of the global market is the growing prevalence of cancer and other chronic diseases, as well as a strong demand for early diagnosis of such diseases for successful treatment.

Furthermore, radiopharmaceuticals are increasingly being used to diagnose and treat chronic diseases in geriatric patients.

Due to growing applications, discoveries, and other factors, it is expected to continue to expand over the next few years.

The global nuclear medicine market size is expected to reach USD 12.6 billion by 2027, expanding at a CAGR of 9.5%, according to a new report by Radiant Insights, Inc. Research and development of advanced technologies by the key players for diagnosis and treatment of diseases is expected to drive the radiopharmaceuticals market.

For instance, in May 2019, GE Healthcare with Indi Molecular, Inc., collaborated to develop Protein Catalyzed Capture (PCC) technology and immune cell-targeted PET tracer candidates.

Moreover, high prevalence of cancer in emerging Asian countries is creating huge demand for radiopharmaceuticals in diagnosing the disease.

For instance, in October 2018, with the support of ASML, The Institute For Radioelements (IRE) developed and built an electron beamline to manufacture medical isotope molybdenum 99 (Mo-99).

In addition, research centers and hospitals are launching novel nuclear medicine techniques to treat various diseases at an affordable cost as compared to the existing treatments.

Further key findings from the study suggest: • In 2019, the SPECT segment had dominated the market owing to integration of SPECT with X-ray/CT that has gained more acceptance and proved to be useful in many clinical situations due to its high accuracy • PET diagnostic nuclear medicine is expected to witness the fastest growth over the forecast period owing to the increasing adoption of high resolution PET scanners • In case of the therapeutic segment, brachytherapy is anticipated to be the fastest growing segment due to the higher radiation protection as compared to other treatment options • The oncology application segment dominated the nuclear medicine market in 2019 owing to the presence of pipeline drugs and high prevalence of cancer • The market in Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and development of radiopharmaceuticals for diagnosis and treatment of various diseases • Key players in the market include companies such as Eckert and Ziegler Group Nordion, Inc.; Bracco Imaging S.p.A.; and GE Healthcare as well as government organizations such as Department of Atomic Energy and Australian Nuclear Science and Technology Organization (ANSTO).